Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Effects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in β-thalassemia/HbE
Authors: Jeeranut Tankanitlert
Noppawan Phumala Morales
Thad A. Howard
Pranee Fucharoen
Russell E. Ware
Suthat Fucharoen
Udom Chantharaksri
Phramongkutklao College of Medicine
Mahidol University
The Institute of Science and Technology for Research and Development, Mahidol University
St. Jude Children's Research Hospital
Keywords: Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Apr-2007
Citation: Pharmacology. Vol.79, No.2 (2007), 97-103
Abstract: In addition to pathophysiological changes, genetic variations can alter drug pharmacokinetics in patients with thalassemia. Numerous drugs are metabolized by UDP-glucuronosyltransferases (UGT) including paracetamol (PCM), a widely used analgesic. Co-occurrence of the UGT1A1 polymorphism (UGT1A1*28) and the UGT1A6 polymorphism (UGT1A6*2) may affect PCM glucuronidation. To elucidate the effect of these combined polymorphisms on the PCM metabolism in thalassemic patients, 15 β-thalassemia/hemoglobin E subjects with three different UGT1A genotypes received a single oral dose of 1,000 mg PCM. Drug disposition was determined by HPLC. Patients who have UGT1A6*2 without UGT1A1*28 showed a significant, lower area under concentration-time curve (AUC0→∞) of PCM, PCM-glucuronide and PCM-sulfate than those of the patients with wild-type UGT1A1 and UGT1A6 (p < 0.05). In addition, a high elimination rate constant and clearance of PCM and its metabolites were also found in these patients (p < 0.05). Ourstudy suggests that a subtherapeutic level of PCM may occur in patients who have UGT1A6*2 without UGT1A1*28. Copyright © 2007 S. Karger AG.
ISSN: 00317012
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.